Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W. Higgs, Barbara White, Wei Zhu et al.|Annals of the Rheumatic Diseases|2011Cited by 412
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsBrandon W. Higgs, Yihong Yao, Wei Zhu et al.|Annals of the Rheumatic Diseases|2013Cited by 168
Genomic signatures characterize leukocyte infiltration in myositis musclesWei Zhu, Yihong Yao, Katie Streicher et al.|BMC Medical Genomics|2012Cited by 40
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinomaLiyan Jiang, Jiaqi Huang, Wei Zhu et al.|BMC Cancer|2014Cited by 32
15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patientsBrandon W. Higgs, K. Ranade, Marlon C. Rebelatto et al.|European Journal of Cancer|2015Cited by 30